The Management Team of the Company has many years of experience in the field of drug discovery and clinical development. Our Scientific Board is composed of scientific experts from independent organizations such as universities and governmental research institutes.
Jose Manuel Mas, CEO at Anaxomics
José Manuel Mas is a Founder and CEO at Anaxomics Biotech. He was previously the EU Head of Collaborative Research Department at RPS Inc. (2008-2012) and Founder and Chief Techology Officer at Infociencia. José Manuel has a degree in Biochemistry, a Master’s degree in Biotechnology and a Phd in Biocomputing, specializing in protein structure, drug design and systems biology. He has a wide experience in the development of biocomputational tools and artificial intelligence techniques.
Mireia Coma (MSc, PhD ), Head of Applied Molecular Physiology
Mireia Coma is the Business Unit Manager and the Head of Molecular Physiology at Anaxomics Biotech SL. She has a degree in Biochemistry, MSc in Experimental Biochemistry and Ph.D. in Health and Life Science. Previously she was a research Fellow at the Memory Unit of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain and at MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. She has a wide experience in preclinical testing for neurodegenerative diseases. As a part of her task in Anaxomics, she is in charge of Anaxomics Consulting Services and drug repositioning pipeline in neurodegenerative diseases.
Judith Farrés (MSc, PhD), Head of Collaborative research
Judith Farrés (MSc, PhD), is the Head of Collaborative Research at Anaxomics Biotech SL. She has a degree in Biochemistry and a Master degree and PhD in Biotechnology. Previously she was research fellow for 6 years at ETH, Zürich. Judith has broad experience in biotechnology techniques and in project management.
Teresa Sardón (MSc, PhD), Head of Analytical services
Teresa Sardón is Business Unit Manager of the analytical services department, where she leads the business development and commercialization of SimsCells analysis platform. She is graduated in Pharmacy at the University of the Basque Country and hold an MS and PhD in Biochemistry from the Universitat Autònoma de Barcelona. Her background includes five years of postdoctoral research at the European Molecular Biology Laboratory (Heidelberg, Germany) and four at the Centre for Genomic Regulation (Barcelona), working in the fields of cellular and molecular biology.
Laura Artigas (MSc), Head of Project Management
Laura Artigas is the Head of Project Management at Anaxomics Biotech SL. She has a degree in Biotechnology and Biochemistry, MSc in Molecular Biotechnology. Previously she belonged to research team of the Molecular Biology and Biochemistry Research Center for Nanomedicine of Hospital de de la Vall d’ Hebrón de Barcelona, Spain. Laura has broad experience in project management and in transferring biological knowledge to the computational domain (building computable descriptions of available molecular, biochemical, and physiological data).
Bruno Brisson (MSc), Strategic Development Advisor
Bruno is in the Life-Sciences business for over 20 years and held several Business Development and General Management positions in biotech and medtech companies. Based in France he collaborates with ANAXOMICS since September 2011 using his extensive background and experience in pre-clinical and early clinical drug development to help structuring the service offers, initiating and making deals with an increasing number of pharma-biotech customers and partners.
Dr Patrick Aloy is a Research Professor at ICREA (Catalan Institution for Research and Advanced Studies) and Principal Investigator of the Structural Bioinformatics & Network Biology Group in the Institute for Research in Biomedicine (IRB Barcelona). He obtained his BSc in Biochemistry, MSc in Biotechnology and PhD in Biochemistry & Molecular Biology from the Autonomous University of Barcelona (Spain), and spent six years as postdoctoral researcher and staff scientist at the European Molecular Biology Laboratory (EMBL), Heidelberg (Germany). His main scientific interests are in the field of structural bioinformatics, in particular, the use of high-resolution three-dimensional structures to reveal the molecular details of how macromolecular complexes and cell networks operate. Dr Aloy has over 80 publications in first-rate journals, with over 5500 citations and remarkable press coverage, illustrating the scientific and social relevance of his work.
Currently Director of Innovation at Hospital Clínic de Barcelona, Scientific Director of the Master in Leadership and Management of Science and Innovation (UB, UAB,UPF Interuniversity program, Barcelona), Former Managing Director of Fundació Clínic per a la Recerca Biomèdica(2006-2008), Managing Director of Novartis Pharma Spain (2004-2006), COO of Novartis Pharma Spain (1997-2004). Several key positions in R&D management in other leading Pharma Industries (Sandoz Pharma, Boehringuer Ingelheim, Bayer, Esteve) (1985-1997), MBA by IESE Corporate training in General Management and Finance at Harvard Business School (1999-2003), Assistant Editor of The Lancet (Spanish edition) (1986-1996). More than 50 publications / book chapters on R&D management and health outcomes research.
Dr. Gomis-Rüth studied organic chemistry at the Chemical Institute of Sarrià (IQS, Barcelona, Spain) and he obtained his B.Sc. (1988) and M.Sc. (1989) there before moving to the Max-Planck-Institute of Biochemistry (MPIB, Martinsried, Germany), where he made his Ph.D. in protein crystallography in the lab of 1988-Nobel laureate Robert Huber (1992).
Postdoctoral stays at the Autonomous University of Barcelona (Spain), the MPIB, and the Molecular Biology Institute of Barcelona (IBMB) of the Spanish Research Council (CSIC) followed before he got a tenured Assistant Professor position at the latter institution.
Since 2008, he is Research Professor CSIC, Director of the Department of Structural Biology of the IBMB, and Head of the Proteolysis Lab at the IBMB, which is located at the premises of the Barcelona Science Park (PCB).
The Proteolysis Lab currently encompasses nine researchers and is centered on the study of proteins by molecular and structural biology to ascertain structure-function relationships following an experimental approach.
Dr. Xavier Daura is Research Professor at the Catalan Institution for Research and Advanced Studies (ICREA) and Principal Investigator of the group for Computational Biology in the Institute of Biotechnology and Biomedicine (IBB) of Universitat Autònoma de Barcelona (UAB). He is BSc in Biological Sciences MSc in Biotechnology and PhD in Biological Sciences by UAB, and was a postdoctoral researcher for six years at the Swiss Federal Institute of Technology (ETH) in Zurich. The main focus of his current research is in the development of new strategies to combat bacterial infections, combining a range of computational and experimental techniques for the identification of candidate bacterial components for synthetic vaccines and antimicrobial targets with new modes of action. Dr Daura has authored over 80 publications, receiving more than 4300 citations.